Our model reasonably characterized the disposition of cefepime in the CNS. Penetration of cefepime into the CNS was variable, at 4-34%, but appeared to be similar to that reported for other cephalosporins administered for meningitis. The concentrations attained by most of our subjects were above the MIC90 of many common nosocomial organisms but may not be sufficient to treat P. aeruginosa or S. aureus. Further studies are warranted to assess the role of cefepime in the treatment of meningitis. In addition, studies should be performed to evaluate the effect of time above the MIC in both serum and CSF and the optimal dose and dosing frequency of cefepime for treatment of meningitis.
Presented at the 54th annual meeting of the American Academy of Neurology, Denver, Colorado, April 17, 2002.
The authors would like to acknowledge David Nicolau, Pharm.D., and Christina Sutherland for their assistance in assaying the cefepime samples, and the neurosurgery housestaff and nurses of the neurotrauma intensive care unit for their assistance in obtaining the samples.Reprint Address
Address reprint requests to Denise H. Rhoney, Pharm.D., Department of Pharmacy, Wayne State University and Detroit Receiving Hospital, 4201 St. Antoine 1B-UHC, Detroit, MI 48201; e-mail: email@example.com.
Pharmacotherapy. 2003;23(3) © 2003 Pharmacotherapy Publications
Copyright © 1999, Pharmacotherapy Publications, Inc., All rights reserved.
Cite this: Disposition of Cefepime in the Central Nervous System of Patients With External Ventricular Drains - Medscape - Mar 01, 2003.